Success Metrics

Clinical Success Rate

100.0%

Based on 6 completed trials

Completion Rate

100%(6/6)

Active Trials

0(0%)

Results Posted

0%(0 trials)

Phase Distribution

Ph phase_1

83%

Ph early_phase_1

17%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution6 total trials

Early Phase 1First-in-human

1(16.7%)

Phase 1Safety & dosage

5(83.3%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

100.0%

6 of 6 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(6)

Detailed Status

Completed6

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

100.0%

Most Advanced

Phase 1

Trials by Phase

Early Phase 11 (16.7%)

Phase 15 (83.3%)

Trials by Status

completed6100%

Recent Activity

0 active trials

Showing 5 of 6

completedphase_1

A Study To Evaluate D1 Receptor Occupancy (RO) Following Single Dose of PF-06412562 In Healthy Male Volunteers

NCT02124213

View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials

NCT03181841Phase 1

Effects of PF-06412562 on Value-based Decision-making in Healthy Individuals

Completed

NCT03665454Phase 1

PF 06412562 in Subjects With Advanced Stage Parkinson's Disease

Completed

NCT03686501Early Phase 1

D1 Receptor Occupancy (RO) Following a Single Dose of PF-06412562

Completed

NCT02006290Phase 1

Efficacy, Safety And Tolerability Study In Subjects With Parkinson's Disease

Completed

NCT02124213Phase 1

A Study To Evaluate D1 Receptor Occupancy (RO) Following Single Dose of PF-06412562 In Healthy Male Volunteers

Completed

NCT01914796Phase 1

A Phase I Trial to Investigate the Safety and Tolerability of PF-06412562

Completed

All 6 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 6